Table 2.

Secondary efficacy endpoints

	Imatinib arm (N=41)	Placebo arm (N=40)	P value
	No. (%)	No. (%)
Response			0·03
Complete response/Partial response	0	0
Stable disease	17 (42)	6 (15)
Progressive disease	19 (46)	29 (73)
Not evaluable	5 (12)	5 (13)
Disease control ≥12 weeks*	13 (32)	2 (5)	0·003
Time to progression	Median 1·8 months (95% CI, 1·7–3·6)	Median 0·9 months (95% CI, 0·9–1·7)	0·002 HR, 0·48 (95% CI, 0·28–0·82)
Overall survival	Median 8·2 months (95% CI, 5·5–12·8)	Median 7·5 months (95% CI, 4·4–12·4)	0·92; HR, 1·00 (95% CI, 0·58–1·83)

^*Complete response or partial response plus stable disease lasting for at least 12 weeks

HR, hazard ratio; CI, confidence interval